BOLD - Audentes Therapeutics, Inc.
| Previous Close | 24.31 |
| Open | 24.31 |
| Bid | 18.00 x 900 |
| Ask | 39.00 x 800 |
| Day's Range | 23.96 - 24.83 |
| 52 Week Range | 17.95 - 46.18 |
| Volume | 639,726 |
| Avg. Volume | 615,170 |
| Market Cap | 1.048B |
| Beta (3Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.39 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.33 |
- PR Newswire•13 days ago
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
- Completed productive initial interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to discuss potential registration pathways for AT132 for the treatment ...
- PR Newswire•16 days ago
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 4, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on January 3, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to five individuals hired by Audentes in December 2018. For more information regarding Audentes, please visit www.audentestx.com.
- PR Newswire•17 days ago
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- PR Newswire•18 days ago
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 2, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with ...
- Simply Wall St.•last month
Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Insider Monkey•last month
Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- American City Business Journals•last month
Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
- PR Newswire•last month
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on December 3, 2018, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to seven individuals hired by Audentes in November 2018. One-fourth of the shares underlying each employee's option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee's continued employment with Audentes on such vesting dates.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT
Q3 2018 Audentes Therapeutics Inc Earnings Call
- Investor's Business Daily•2 months ago
These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
- GlobeNewswire•2 months ago
Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•2 months ago
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- Associated Press•2 months ago
Audentes Therapeutics: 3Q Earnings Snapshot
The San Francisco-based company said it had a loss of 97 cents per share. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- PR Newswire•2 months ago
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
- Completed Cohort 2 enrollment in ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-linked Myotubular Myopathy - Plan interactions with the U.S. Food and Drug Administration (FDA) and ...
- PR Newswire•2 months ago
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Louis G. Lange, M.D., Ph.D. appointed as Lead Independent Director SAN FRANCISCO , Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing ...
- PR Newswire•3 months ago
Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- PR Newswire•3 months ago
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO , Oct. 10, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients ...
- Benzinga•3 months ago
The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 9) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- PR Newswire•3 months ago
Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients ...
- American City Business Journals•3 months ago
Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.
- Zacks•3 months ago
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- American City Business Journals•4 months ago
Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.
- PR Newswire•4 months ago
Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society
SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be ...
- PR Newswire•4 months ago
Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
- Significant continued improvements in neuromuscular and respiratory function observed in all treated patients, with follow-up assessments ranging from 4 to 48 weeks - Three patients have achieved complete ...
